Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study

PLoS One. 2019 Apr 25;14(4):e0215738. doi: 10.1371/journal.pone.0215738. eCollection 2019.

Abstract

Background: Extraintestinal manifestations (EIM) contribute significantly to the burden of disease in inflammatory bowel disease (IBD). Pain is a leading symptom in IBD and could be seen as an EIM itself. Treatment of IBD associated pain is challenging and insufficiently studied. A better knowledge on the association of pain and IBD specific treatment is warranted to improve the management of IBD patients.

Methods: All patients of the Swiss IBD Cohort Study (SIBDCS) (n = 2152) received a questionnaire regarding pain localization, pain character, and the use of IBD specific medication.

Results: 1263 completed questionnaires were received. Twenty-one out of 184 patients (10%) receiving anti-TNF treatment compared to 142 out of 678 patients (21%) not receiving anti-TNF medication reported elbow pain (p = 0.002) while 28 out of 198 patients (14%) receiving steroid treatment significantly more often reported elbow pain compared to 59 from 696 patients (8%) not receiving steroids (p = 0.021). Furthermore, we found significantly more female patients under anti-TNF treatment to report knee/ lower leg pain and ankle/ foot pain compared to their male counterparts (36% vs. 20% and 22% vs. 10%, respectively, p = 0.015 for both comparisons). The frequency of knee, lower leg, ankle and foot pain was especially low in male patients under anti-TNF treatment, indicating a high benefit of male patients from anti-TNF therapy regarding EIM.

Conclusions: The frequency of elbow pain was lower in IBD patients treated with anti-TNF but higher in patients treated with steroids.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Arthralgia / epidemiology*
  • Arthralgia / etiology
  • Arthralgia / prevention & control
  • Elbow Joint
  • Female
  • Follow-Up Studies
  • Foot Joints
  • Humans
  • Inflammatory Bowel Diseases / complications
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / immunology
  • Knee Joint
  • Male
  • Middle Aged
  • Prevalence
  • Prospective Studies
  • Risk Factors
  • Sex Factors
  • Switzerland / epidemiology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Anti-Inflammatory Agents
  • TNF protein, human
  • Tumor Necrosis Factor-alpha

Grants and funding

This research was supported by a research grant from the Swiss National Science Foundation (http://www.snf.ch/de/Seiten/default.aspx) to GR for the Swiss IBD Cohort (Grant No. 3347CO-108792). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.